You are here:

Archived: Pegvisomant (Somavert®)


Following a full submission.

Pegvisomant (Somavert) is not recommended for use within NHS Scotland for the treatment of patients with acromegaly who have had an inadequate esponse to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 concentrations or was not tolerated. visomant reduces IGF-1 levels significantly, as well as improving some of the clinical manifestations of acromegaly. Although it is acknowledged that this is an orphan drug the cost-effectiveness is Poor.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Pegvisomant (Somavert®)
SMC Drug ID: 158/05
Manufacturer: Pfizer Ltd
Indication: Acromegaly
BNF Category:
Sub Category: 6.5 Hypothalamic and pituitary hormones and anti-oestrogens
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 May 2005

Current Advice

Resubmission 13 November 2017

Archived Advice

Resubmission 5 May 2006